盐酸咪达唑仑(Midazolam Hydrochloride) - 药物靶点：GABAA receptor_在研适应症：癫痫持续状态，麻醉，癫痫发作_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Midazolam hydrochloride (USAN)、Ozalin、NSC-751451

+ [9]

靶点

GABAA receptor

作用方式

激动剂

作用机制

GABAA receptor激动剂(γ-氨基丁酸 A 受体激动剂)

治疗领域

神经系统疾病其他疾病

在研适应症

癫痫持续状态麻醉癫痫发作+ [1]

非在研适应症-

原研机构

F. Hoffmann-La Roche Ltd.

在研机构

Neuraxpharm Pharmaceuticals S.L.

Rafa Laboratories Ltd.

江苏恩华药业股份有限公司

+ [2]

非在研机构

Shire Plc

Meridian Medical Technologies LLCHoffmann-La Roche, Inc.

权益机构

Nordic Pharma Group

Takeda Pharmaceutical Co., Ltd.

Neuraxpharm

+ [3]

最高研发阶段批准上市

首次获批日期

美国 (1985-12-20),

麻醉镇静

最高研发阶段(中国)批准上市

特殊审评优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C18H14Cl2FN3

InChIKeyPLYSCVSCYOQVRP-UHFFFAOYSA-N

CAS号59467-96-8

关联

799

项与盐酸咪达唑仑相关的临床试验

NCT05945147

/ Withdrawn临床2期IIT

Feasibility Study Comparing a Ketamine and Midazolam Infusion to a Midazolam-Only Infusion for Complex Regional Pain Syndrome

This study will assess the feasibility of administering ketamine plus midazolam or midazolam alone, when infused over 5 days in an outpatient setting, to adults with complex regional pain syndrome (CRPS).

开始日期2099-01-01

申办/合作机构

Stanford University

NCT07095842

/ Recruiting临床2/3期IIT

Efficacy of Add-on Ketamine With Second-dose Midazolam for Prehospital Treatment of Epileptic Children With Status Epilepticus

The goal of this pragmatic, decentralized, pre-consented, event-driven, randomized controlled trial is to investigate the efficacy of add-on ketamine to second-dose midazolam for prehospital treatment of epileptic children with convulsive status epilepticus.

开始日期2025-08-03

申办/合作机构

Sohag University

NCT06692192

/ Recruiting临床1期IIT

Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study)

The goal of this clinical trial is to learn about the role that inducing neuroplasticity (the brain's ability to adapt and change) plays in the behavioral effects of psilocybin in people who have experienced a mild decline in emotional wellbeing.
Researchers will compare different doses of psilocybin combined with midazolam or placebo to see what dose induces increased wellbeing.
Participants will:
* Receive one of four possible combinations of medications
* Undergo an MRI
* Complete questionnaires
* Undergo transcranial magnetic stimulation (TMS) and EEG

开始日期2025-08-01

申办/合作机构

University of Wisconsin Madison

100 项与盐酸咪达唑仑相关的临床结果

登录后查看更多信息

100 项与盐酸咪达唑仑相关的转化医学

登录后查看更多信息

100 项与盐酸咪达唑仑相关的专利（医药）

登录后查看更多信息

10,014

项与盐酸咪达唑仑相关的文献（医药）

2025-09-02·INTERNATIONAL JOURNAL OF ENVIRONMENTAL ANALYTICAL CHEMISTRY

Development and application of a sustainable approach for the determination of 95 pharmaceutical substances and metabolites in urban wastewater by means of ultra-high-performance liquid-chromatography-tandem mass spectrometry

作者: Vincenti, Marco ; Gerace, Enrico ; Minella, Marco ; Privitera, Dana ; Salomone, Alberto ; Massano, Marta ; Alladio, Eugenio

In the last few years, the interest in pharmaceutical drugs and their metabolites as environmental pollutants is gaining growing importance.Regular monitoring and timely actions are decisive to implement appropriate water resource management strategies and to evaluate the efficiency of traditional or innovative wastewater treatment plants (WWTPs).This study describes the development and validation of an anal. procedure using 10 mL sample volume followed by direct-injection in ultra-high-performance liquid chromatog.-tandem mass spectrometry (UHPLC-MS/MS) for the simultaneous determination of 95 pharmaceutical drugs and 10 of their main metabolites in wastewater.Adequate sensitivity was recorded for all target analytes, with limits of detection below 5 ng/L for 60 out of 95 analytes and recoveries exceeding 80% for all the analytes under study.A total of 42 target analytes were detected in almost all sites, and limited differences were observed among several pharmaceutical drug arrays found at different sampling sites.In addition, an abatement yield higher than 50% was observed for only 12 of the 42 detected substances.The procedure, which combined direct injection and small sample volume collection, showed great potential and efficiency for the high-performance determination of pharmaceutical drugs in wastewater.

2025-09-01·BIOMATERIALS

Bioprinted high cell density liver model with improved hepatic metabolic functions

Article

作者: Feng, Gen-Sheng ; Meng-Saccoccio, Tobias ; Lu, Ting-Yu ; Xiang, Yi ; Chen, Shaochen ; Sun, Yazhi ; Shen, Erin Nicole ; Lyu, Cheng ; Ji, Yichun

In vitro liver tissue models are valuable for studying liver function, understanding liver diseases, and screening candidate drugs for toxicity and efficacy. While three-dimensional (3D) bioprinting shows promise in creating various types of functional tissues, current efforts to engineer a functional liver tissue face challenges in replicating native high cell density (HCD) and maintaining long-term cell viability. HCD is crucial for establishing the cell-cell interactions necessary to mimic the liver's metabolic and detoxification functions. However, HCD bioinks exacerbate light scattering in light-based 3D bioprinting. In this study, we incorporated iodixanol into our bioink formulation to minimize light scattering, enabling the fabrication of hepatic tissue constructs with an HCD of 8 × 10⁷ cells/mL while maintaining high cell viability (∼80 %). The printed dense hepatic tissue constructs showed enhanced cell-cell interactions, as evidenced by increased expression of E-cadherin and ZO-1. Furthermore, these constructs promoted albumin secretion, urea production, and P450 metabolic activity. Additionally, HCD hepatic tissue inactivated the YAP/TAZ pathway via cell-cell interactions, preserving primary hepatocyte functions. Further screening revealed that hepatocytes in the dense model were more sensitive to drug treatments than those in a lower-density hepatic model, highlighting the importance of HCD in recapitulating the physiological drug responses. Overall, our approach represents a significant advancement in liver tissue engineering, providing a promising platform for the development of physiologically relevant in vitro liver models for drug screening and toxicity testing.

2025-08-01·EPILEPSY RESEARCH

Adequate and inadequate dosing of anti-seizure medications in status epilepticus

Article

作者: Smith, Melissa ; Schrader, Susan

BACKGROUND:

Status epilepticus (SE) is defined as five or more minutes of continuous seizures or two or more discrete seizures with incomplete recovery of consciousness.¹ The incidence of SE in the United States ranges from 18.3 to 41 per 100,000 patients per year². Reviews of SE clinical literature demonstrate that 70-75 % of patients did not receive an adequate dose of benzodiazepine according to clinical guidelines. Underdosing of benzodiazepines increases the risk of refractory SE and unfavorable outcomes.^8-9 METHODS: This single center retrospective cohort study evaluated the dosing of benzodiazepines and other anti-seizure medications in adult patients with SE. The primary outcomes were incidence of breakthrough seizures in patients with appropriate dosing benzodiazepines compared to inappropriate dosing of benzodiazepines within 24 h of the first dose and incidence of breakthrough seizures in patients with appropriate loading dose of maintenance anti-seizure medication compared to inappropriate loading dose of anti-seizure medication within 24 h of the first dose.

RESULTS:

Thirty-eight patients received adequate benzodiazepine dosing compared to 155 with inadequate dosing. Eighty-seven percent of patients with adequate dosing of benzodiazepine experienced a breakthrough seizure compared to 84 % of patients with inadequate dosing (p = 0.62). Sixty-three percent of patients with adequate dosing of benzodiazepines required first non-benzodiazepine anti-seizure medication compared to 63 % of patients with inadequate dosing (p = 0.76). Breakthrough seizures within 24 h after the first load of non-benzodiazepine anti-seizure medication occurred in 21 % of patients in the adequate dosing group compared to 28 % in the inadequate dosing group (p = 0.73).

CONCLUSION:

While benzodiazepines and rescue anti-seizure medications are frequently underdosed in patients with status epilepticus, there was no difference in recurrent seizures comparted to those with adequate dosing.

16

项与盐酸咪达唑仑相关的新闻（医药）

2025-07-14

·GlobeNewswire-Health Care

Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies

Drug-drug interaction (“DDI”) clinical studies help identify the potential for side effects, or in some cases, reduced therapeutic efficacy, that may be caused by interactions between different drugs. The market leading epidermal growth factor receptor (“EGFR”) and anaplastic lymphoma kinase (“ALK”) inhibitors for the treatment of non-small cell lung cancer (“NSCLC”) are substrates of the Cytochrome P450 (“CYP”) enzyme CYP3A, and therefore their combination with drugs that are strong inducers of CYP3A is to be avoided, or is contraindicated. As per the International Council for Harmonization (“ICH”) M12, topline results from the NXP900 DDI clinical study classify NXP900 as a weak inhibitor of CYP3A; these results support the combination strategy of NXP900 with EGFR/ALK Inhibitors in NSCLC and potentially additional combinations. July 08, 2025 -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the successful completion of a clinical DDI study in healthy volunteers for NXP900, supporting NXP900’s potential as a combination partner with leading therapies. Key Study Objective: To determine whether NXP900 is an inducer of CYP3A, and if so, to classify its induction as weak, moderate or strong as per ICH M12 guidelines Study Population: 14 healthy volunteers Key Pharmacokinetics Result: NXP900 increased the concentration of Midazolam, a known CYP3A sensitive substrate, by Key Safety Results: No serious or severe adverse events were reported in this study; diarrhea and non-infection related increases in white blood cell counts were the most common adverse events reported, all mild to moderate in intensity Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “As we’re now completing the dose escalation Phase 1a study of NXP900 in patients with advanced cancers, the data generated to date, including the preclinical and mechanistic data, the clinical safety, pharmacokinetics and pharmacodynamics data, and now the clinical DDI data, strongly support advancing NXP900 into the Phase 1b program, set to begin in the coming weeks. In the Phase 1b we plan to test the therapeutic potential of NXP900 as a single agent and in non-chemotherapy based combinations with leading EGFR and ALK drugs in patients that may derive substantial clinical benefit from treatment with NXP900, as their cancers are expected to be sensitive to inhibition of SRC/YES1.” Mr. Bentsur concluded, “We believe that NXP900’s differentiating properties, mainly the type 1.5 mechanism of action which combines potent and selective inhibition of both the kinase activity and scaffolding properties of the SRC family kinases, should translate into a wide therapeutic window, and we are excited about the future of NXP900.” Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two clinical-stage drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900's unique mechanism of action enables the inhibition of both the catalytic and scaffolding functions of the SRC kinase thereby providing complete shutdown of the signaling pathway. NXP900 is currently in a Phase 1a dose escalation study. The content above comes from the network. if any infringement, please contact us to modify.

临床研究

2025-01-07

·PRNewswire

Neuraxpharm to further grow branded business with the acquisition of two leading narcolepsy treatments, Provigil® and Nuvigil®

Provigil® (modafinil) and Nuvigil® (armodafinil), two of the most trusted and widely prescribed brands in the narcolepsy category, will increase Neuraxpharm's global CNS presence and support market entry into new territories including Australia BARCELONA, Spain and DÜSSELDORF, Germany, Jan. 7, 2025 /PRNewswire/ -- Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces today that it has acquired at the end of December 2024 Provigil® (modafinil) and Nuvigil® (armodafinil), both of which are indicated for the treatment of Excessive Daytime Sleepiness (EDS) in adults with narcolepsy. Neuraxpharm has acquired these products in most markets outside the US^. Provigil's main market is Europe, with significant sales in France, Spain and Italy. Nuvigil is present in international markets with significant sales in Australia and Mexico. Both Provigil and Nuvigil are orally administered CNS stimulants indicated to improve wakefulness and reduce Excessive Daytime Sleepiness (EDS) in adult patients with narcolepsy, both with and without cataplexy. This acquisition is in line with Neuraxpharm's strategy to grow strong CNS brands and bring them to increasing numbers of patients worldwide. It will enable entry into new territories such as Australia, where Neuraxpharm also plans to launch first-in-class multiple sclerosis treatment ublituximab (BRIUMVI®), and will furthermore reinforce Neuraxpharm's presence in Mexico, where the Company established an office in 2023. The transaction follows the acquisition from Sanofi of two established product portfolios in 2023 and the securing of a landmark partnership with TG Therapeutics also in 2023 to commercialise ublituximab outside the US*. In 2020, Neuraxpharm acquired market-leading child epilepsy treatment Buccolam® (oromucosal midazolam) from Takeda, and in September last year Neuraxpharm received a positive CHMP opinion from the European Medicine Agency to extend Buccolam's indication to include the treatment of epilepsy in adults. Dr. Jörg-Thomas Dierks, CEO of Neuraxpharm, commented: "Today's acquisition is an example of how Neuraxpharm can harness its neurology-focused approach, broad international platform and entrepreneurial capabilities to expand strong CNS brands. These two leading narcolepsy treatments will be added to our broad and growing CNS portfolio. We will leverage our specialisation and reach to grow these products in existing and new markets, thereby bringing market-leading treatments to more CNS patients with unmet needs around the world." No financial details of the transaction have been disclosed. ^ Republic of Korea, Japan, Thailand and the United States are not included in this acquisition. * Territories outside the United States, Canada, Mexico, and excluding certain Asian countries previously partnered. About the Neuraxpharm Group Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of the central nervous system (CNS), including both psychiatric and neurological disorders. It has a unique understanding of the CNS market built over 35 years. Neuraxpharm is constantly innovating, with new products and solutions to address unmet patient needs and is expanding its portfolio through its pipeline, partnerships, and acquisitions. The company has c.1,000 employees and develops and commercializes CNS products through a direct presence in more than 20 countries in Europe, two in Latin America, one in the Middle East, and globally via partners in more than 50 countries. Neuraxpharm is backed by funds advised by Permira. Neuraxpharm manufactures many of its pharmaceutical products at Neuraxpharm Pharmaceuticals (formerly Laboratorios Lesvi) in Spain. For more information, please visit SOURCE Neuraxpharm WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准并购临床结果

2023-02-27

·米内网

【获批】江苏药企发力，拿下9亿麻醉剂首家过评

精彩内容近日，江苏恩华药业发布公告称，控股子公司江苏远恒药业的依托咪酯中/长链脂肪乳注射液获批上市，该产品按4类仿制获批视同过评。依托咪酯是一款畅销麻醉剂，2021年在中国公立医疗机构终端销售额超过9亿元。公告中提到，依托咪酯中/长链脂肪乳注射液用于全身麻醉诱导：成人、6个月以上婴幼儿、儿童和青少年。图1：目前已上市的依托咪酯制剂来源：米内网新版数据库米内网数据显示，目前已上市的依托咪酯制剂主要为注射剂，恩华药业、恒瑞医药以及贝朗三足鼎立，本次获批的依托咪酯中/长链脂肪乳注射液为该品种首个过评产品。图2：依托咪酯注射剂的销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局在中国城市公立医院、县级公立医院、城市社区中心及乡镇卫生院（简称中国公立医疗机构）终端，依托咪酯在2013-2021年的销售额均保持正增长态势，2021年达到峰值9.7亿元，2022上半年增速为6.06%，江苏恩华药业以超过90%的市场份额领军。表1：江苏恩华药业已过评（含视同过评）的产品来源：米内网中国申报进度（MED）数据库截至2月24日，江苏恩华药业已过评（含视同过评）的产品达18个，枸橼酸舒芬太尼注射液、利培酮分散片、氯氮平片、氯硝西泮片、咪达唑仑注射液、盐酸咪达唑仑口服溶液、依托咪酯中/长链脂肪乳注射液（按产品名统计）为首家过评。资料来源：NMPA官网、米内网数据库注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至2月24日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

上市批准

100 项与盐酸咪达唑仑相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00696	盐酸咪达唑仑	N05CD08	DB00683

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
癫痫持续状态	美国	Meridian Medical Technologies LLC	2018-09-14
癫痫发作	欧盟	Neuraxpharm Pharmaceuticals S.L.	2011-09-04
癫痫发作	冰岛	Neuraxpharm Pharmaceuticals S.L.	2011-09-04
癫痫发作	列支敦士登	Neuraxpharm Pharmaceuticals S.L.	2011-09-04
癫痫发作	挪威	Neuraxpharm Pharmaceuticals S.L.	2011-09-04
麻醉	美国	Hoffmann-La Roche, Inc.	1985-12-20
镇静	美国	Hoffmann-La Roche, Inc.	1985-12-20

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05610969 (CTgov)	临床1/2期	表现焦虑 \| 神经阻滞 \| 焦虑症	36	Music (Music Group)	淵淵糧簾鹹簾鏇廠壓積(廠衊簾憲壓襯鏇蓋膚範) = 獵廠餘夢鑰鹹構醖廠築膚壓壓鬱鏇襯簾壓衊夢 (築鑰齋繭願廠衊壓鏇夢, 7.02) 更多	-	2025-05-14
				Midazolam (Midazolam Group)	淵淵糧簾鹹簾鏇廠壓積(廠衊簾憲壓襯鏇蓋膚範) = 壓觸顧選醖鬱繭網築遞膚壓壓鬱鏇襯簾壓衊夢 (築鑰齋繭願廠衊壓鏇夢, 9.22) 更多
NCT04068948 (CTgov)	临床4期	镇静 \| 龋齿	37	Meperidine+Midazolam+Hydroxyzine (Midazolam, Hydroxyzine, Meperidine)	構網醖鑰選鏇淵積淵窪 = 繭膚醖網窪遞衊鏇醖遞膚淵鑰製繭蓋齋鑰衊夢 (繭艱蓋繭糧醖糧醖餘夢, 網鏇積衊壓醖夢網夢蓋 ~ 製築鬱選鏇齋壓鹹積壓) 更多	-	2023-12-05
				Midazolam+Hydroxyzine (Midazolam, Hydroxyzine)	構網醖鑰選鏇淵積淵窪 = 範獵鏇醖鬱襯築鏇選蓋膚淵鑰製繭蓋齋鑰衊夢 (繭艱蓋繭糧醖糧醖餘夢, 鏇積製觸築築簾願糧鬱 ~ 顧糧鏇憲積蓋糧醖憲選) 更多
NCT02856698 (MIMO, CTgov)	临床4期	急性肺水肿	111	Midazolam (Midazolam)	夢糧膚簾窪鹹獵網遞鹹 = 餘糧網獵齋艱願鹹廠廠願範鹹憲餘淵觸觸襯遞 (獵鹹窪衊網窪醖餘衊襯, 選膚繭遞壓構範願網遞 ~ 網鑰築簾窪醖鹽夢顧鑰) 更多	-	2022-05-19
				Morphine (Morphine)	夢糧膚簾窪鹹獵網遞鹹 = 糧製醖鑰艱餘範選糧鬱願範鹹憲餘淵觸觸襯遞 (獵鹹窪衊網窪醖餘衊襯, 齋選遞鑰網窪襯衊觸蓋 ~ 憲網選範構鏇鹽願鹽糧) 更多
NCT03085563 (CTgov)	临床4期	脓肿 \| 镇静 \| 撕裂	63	Nitrous Oxide (Nitrous Oxide)	獵壓淵獵獵壓鑰鑰蓋製(憲簾鏇艱鬱構簾憲製鹽) = 餘製顧顧廠範夢鹹壓網鬱鹹窪壓醖膚繭蓋獵構 (遞願簾衊鹹鏇廠壓壓鬱, 製鹽積夢遞積鏇膚遞鏇 ~ 壓製簾遞蓋鏇蓋繭憲觸) 更多	-	2022-05-10
				Midazolam (Intranasal Midazolam)	獵壓淵獵獵壓鑰鑰蓋製(憲簾鏇艱鬱構簾憲製鹽) = 選齋簾鏇衊淵積膚鏇顧鬱鹹窪壓醖膚繭蓋獵構 (遞願簾衊鹹鏇廠壓壓鬱, 顧夢構壓鹽醖齋齋積窪 ~ 夢醖鹹餘鏇鏇鑰積遞繭) 更多
NCT03336450 (CTgov)	临床3期	癫痫持续状态	3	MHOS/SHP615	範選淵窪製積遞積醖鹹 = 鑰憲構淵鹹鏇鑰窪鏇壓積艱願壓襯繭願網網壓 (夢鬱壓築構壓淵鹹繭窪, 選膚艱願廠廠簾鬱齋鏇 ~ 範餘蓋齋願鹽獵積窪製) 更多	-	2021-09-14
NCT02356705 (CTgov)	临床4期	镇静	42	saline placebo (Saline Placebo)	夢觸繭糧壓齋糧構選顧 = 壓艱繭遞壓鑰選顧簾夢廠餘壓觸鬱膚顧構鹽觸 (膚顧積構願繭選選襯構, 範衊蓋鹹選獵憲衊鹽積 ~ 鑰窪鹽鹹鏇網鹽積窪鬱) 更多	-	2021-02-25
				Midazolam (Nasal Midazolam Only)	夢觸繭糧壓齋糧構選顧 = 膚鑰觸鹽簾網範壓選獵廠餘壓觸鬱膚顧構鹽觸 (膚顧積構願繭選選襯構, 觸構願鏇窪獵積蓋選顧 ~ 鑰範糧簾鏇壓淵壓夢淵) 更多
NCT02486328 (CTgov)	临床4期	胃肠功能紊乱 \| 认知	103	Meperidine+Midazolam (Group MM)	遞鹽遞窪壓鹽網鏇壓醖(築壓繭範範鑰顧衊膚壓) = 餘衊鑰鏇窪衊積鏇鏇構齋齋鹹蓋鑰窪餘獵齋衊 (淵齋窪壓襯簾蓋餘衊淵, 10.6) 更多	-	2020-09-03
				Propofol+Remifentanil (Group RP)	遞鹽遞窪壓鹽網鏇壓醖(築壓繭範範鑰顧衊膚壓) = 蓋壓獵積製繭網積遞糧齋齋鹹蓋鑰窪餘獵齋衊 (淵齋窪壓襯簾蓋餘衊淵, 6.8) 更多
NCT03246724 (CTgov)	临床4期	镇静	327	Sodium chloride 0.9%+Microcrystalline Cellulose+Triazolam+Midazolam (Cataract Procedures)	獵膚糧蓋築觸願積鬱襯(繭糧製夢夢遞積鑰築築) = 簾鬱憲窪顧淵夢齋觸醖衊醖艱築淵窪夢遞艱憲 (蓋壓鹹網廠觸壓積壓觸, 0.57) 更多	-	2020-08-19
				Sodium chloride 0.9%+Microcrystalline Cellulose+Triazolam+Midazolam (Retina Procedures)	獵膚糧蓋築觸願積鬱襯(繭糧製夢夢遞積鑰築築) = 製艱餘獵獵構廠鹹鑰鑰衊醖艱築淵窪夢遞艱憲 (蓋壓鹹網廠觸壓積壓觸, 0.72) 更多